Lundbeck
6 Parkway North
Deerfield
Illinois
60015
United States
Tel: 224-507-1000
Website: https://www.lundbeck.com/global
About Lundbeck
At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with a U.S. home office in Deerfield, Ill., Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world’s most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and we continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.
Offices in:
- Deerfield, IL - Lundbeck US Home Office
- LaJolla, CA - Lundbeck La Jolla Research Center, Inc.
- Bothell, WA - Lundbeck Seattle BioPharmaceuticals, Inc
Diversity matters, and inclusion creates powerful organizations To ensure that we reflect the diversity of our patients and their needs, we are focused on creating the context, culture, and systems where all Lundbeck employees - no matter who and where they are - can be their authentic self and perform at their best. In practice, this means that individuals feel empowered not despite their differences but because of them. We know that people are sometimes put into boxes - some of these boxes are of our own choosing and some of these boxes are chosen for us. For this reason, Lundbeck is taking a systematic, business-led approach to D&I that looks into and breaks down these boxes. Our bold action on inclusion includes an ambitious two-year plan that enables equality of opportunity through fairness and transparency, promotes openness, tackles bias and discrimination, and fosters belonging through our unique Lundbeck culture. From the highest levels of Lundbeck to the shop floor, we are working to ensure D&I is an integrated practice and mindset. "We win together. Lundbeck is a place where you grow and thrive – personally and professionally. We embrace the uniqueness of individuals, knowing we are stronger when every brain is in the game." Deborah Dunsire, CEO
Benefits
Lundbeck offers a competitive benefits package that includes:
• Medical, dental, vision effective day 1 of employment
• Generous vacation, sick leave, holiday shut down and company paid holidays
• 401k match with immediate vesting
• Parental Leave
• Hybrid work model for office-based roles
To view more details about our Benefits, please click on the link below.
Lundbeck 2023 Benefits Summary
Sustainable Development Goals
In 2020, we based the key aspects of our sustainability strategy on the UN Sustainable Development Goals (SDGs). We found we have a significant impact on seven of the 17 Goals:
• Goal 3: Good Health and Well-being
• Goal 5: Gender Equality
• Goal 8: Decent Work and Economic Growth
• Goal 10: Reduced Inequalities
• Goal 12: Responsible Consumption and Production
• Goal 13: Climate Action
• Goal 16: Peace, Justice, and Strong Institutions
Key examples are Goal 3 that is closely linked to our corporate purpose and dedication to restore brain health and Goal 13 that drives our efforts to prepare for a zero emissions future. We will use our influence and act to promote Goals 5, 8, 12 and 16. Across our sustainability actions, we are seeking partnerships with others to enable change and maximize impact (Goal 17).
Who We Are
A highly specialized pharmaceutical company that has conducted neuroscience research for more than 70 years. We develop innovative treatments to restore brain health and transform the lives of millions of people worldwide.
What We Strive For
Global leadership in brain health. Whatever your area of specialization, you will be part of our company-wide commitment to develop and advance treatments that improve the lives of people with brain disease.
What Drives Us
A culture of innovation, collaboration, and respect. We inspire curiosity, expect integrity, and pursue our achievements through knowledge-sharing, patient engagement, and the passion to deliver our end goal.
Our Societal Commitment
We understand we carry a huge responsibility for the societies we serve, and use our knowledge and voice to raise awareness, challenge standards, and increase opportunities – for patients and each other. We are at the forefront of treatment innovation, and together we continue to make a difference to people living with brain diseases.
Our Investment in You
As one way we invest in your career, we offer our employees a competitive compensation and benefit package that matches benchmark and general market conditions in our individual business locations.
Employee Satisfaction
The success of our strategy, “Expand and Invest to Grow Lundbeck” hinges on our combined competencies – and competence hinges on highly qualified and motivated employees. Our Employee Satisfaction Survey (ESS) gives us the pulse on employee motivation by asking about key elements in our work lives including management, work climate and development opportunities. We follow up on the ESS with concrete initiatives aimed at maintaining our focus on our unique workplace culture and providing personalized and aligned development opportunities for our employees.
Our Beliefs
• Patient-driven We put patients at the center of our fight for health and human dignity.
• Courageous We dare to confront unsolved healthcare challenges.
• Ambitious We set high expectations for ourselves because people in need have high expectations of us.
• Passionate We persist in developing life-changing therapies because life should not be interrupted by brain disease.
• Responsible We act with respect and integrity in everything we do
CONNECT
Every Brain in the Game
207 articles about Lundbeck
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
-
AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache
6/13/2020
Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose
-
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
-
AllianceRx Walgreens Prime one of only two specialty pharmacies to distribute Vyepti™, the first and only intravenous preventive treatment for migraine
5/19/2020
New medicine one of several limited distribution drugs available through specialty pharmacy
-
BioSpace Global Roundup, April 9
4/9/2020
Biopharma companies from across the globe provide updates to their business operations and pipelines. -
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds
3/25/2020
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds The PROMISE 2 study met its primary endpoint, with VYEPTI demonstrating statistically significant reductions in mean monthly migraine days (MMD) after the first dose over months 1-3 The preventive effects of VYEPTI were demonstrated as early as day 1 post-infusion and sustained thro
-
FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine
2/22/2020
In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Lundbeck selects Discngine’s 3decision® platform to leverage complex protein-ligand 3D structure data in the discovery of new treatments for brain diseases
9/4/2019
Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.
-
P1vital announces launch of the Reward Task Optimisation Consortium - RTOC
7/22/2019
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
-
Lundbeck Tops Corporate Reputation Rankings for Fourth Consecutive Year
5/31/2019
Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.
-
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
-
Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
1/7/2019
Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.
-
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners
9/24/2018
Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
5/23/2018
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.
-
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
-
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.